The objectives of the Administrative Core are to provide four sources of support for the programmembers: (1) fiscal management, (2) staff specialist services, (3) facilitate communication, and (4) serve ascoordination point and communication center for the FDA and the coordination mechanism for scheduling andrunning data safety and monitoring board (DSMB) meetings. The core has the following specific aims:
Specific Aim 1 - Manage Fiscal Affairs. The core will provide up-to-the-date support for the fiscal affairs ofthe program. This includes personnel management of other support, setting up and monitoring fund codes,providing monthly balance sheets to program project directors and managing travel reimbursements.
Specific Aim 2 - Provide staff specialist services. The services include arranging for travel to grant relatedscientific meetings and conferences, organizing group meetings and seminars, and organization of thequarterly dinner meetings and the annual research retreat. This service will also maintain current biosketchesand facilities statements for all program directors..
Specific Aim 3 - Facilitate Inter-program communication. Minutes are taken at all program meetings, whichinclude ACTION ITEMS that are tracked until completed. All communications are posted at a members onlywebsite (password protected) as well as being distributed by email. Other important documents, such asprotocols, DSMB reports, case report forms, blank informed consent forms and project related data will be kepton the website for easy access by all program participants.
Specific Aim 4 - Serve as the central coordination point for communications with the FDA. The programcurrently has three IDEs supporting ongoing clinical trials. There will be additional IDEs filed during the nextfunding cycle. The Administrative Core will handle all correspondence with the FDA and will coordinate thepreparation of new applications and reports, using input from the appropriate program directors offices. Thiscore will also organize the DSMB meetings, in collaboration with Core 2. The reports from the DSMB will bedistributed to program members and posted on the secure website for future reference.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA042745-21
Application #
7719688
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
21
Fiscal Year
2007
Total Cost
$150,101
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Stauffer, Paul R; van Rhoon, Gerard C (2016) Overview of bladder heating technology: matching capabilities with clinical requirements. Int J Hyperthermia 32:407-16
Juang, Titania; Stauffer, Paul R; Craciunescu, Oana A et al. (2014) Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer. Int J Hyperthermia 30:176-83
Inman, Brant A; Stauffer, Paul R; Craciunescu, Oana A et al. (2014) A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia 30:171-5
Angele, Martin K; Albertsmeier, Markus; Prix, Niclas J et al. (2014) Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. Ann Surg 260:749-54; discussion 754-6
Zagar, Timothy M; Vujaskovic, Zeljko; Formenti, Silvia et al. (2014) Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia 30:285-94
Viglianti, Benjamin L; Dewhirst, Mark W; Boruta, R J et al. (2014) Systemic anti-tumour effects of local thermally sensitive liposome therapy. Int J Hyperthermia 30:385-92
Oliveira, Tiago R; Stauffer, Paul R; Lee, Chen-Ting et al. (2013) Magnetic fluid hyperthermia for bladder cancer: a preclinical dosimetry study. Int J Hyperthermia 29:835-44
Dewhirst, Mark W; Landon, Chelsea D; Hofmann, Christina L et al. (2013) Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes. Surg Oncol Clin N Am 22:545-61
Oliveira, Tiago R; Stauffer, Paul R; Lee, Chen-Ting et al. (2013) Preclinical Dosimetry of Magnetic Fluid Hyperthermia for Bladder Cancer. Proc SPIE Int Soc Opt Eng 8584:1656985
van Rhoon, Gerard C; Samaras, Theodoros; Yarmolenko, Pavel S et al. (2013) CEM43°C thermal dose thresholds: a potential guide for magnetic resonance radiofrequency exposure levels? Eur Radiol 23:2215-27

Showing the most recent 10 out of 227 publications